Vianautis Bio Announces $25 Million Series A Financing To Drive The Next Generation Of Genetic Nanomedicines
Vianautis Bio Announces $25 Million Series A Financing To Drive The Next Generation Of Genetic Nanomedicines
11/13/23, 7:02 AM
Location
cambridgeMoney raised
$25 million
Industry
biotechnology
health care
ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, is excited to announce the successful completion of its Series A funding round, raising $25 million (£20 million). Formerly known as SomaServe, ViaNautis has secured support from a consortium of prominent global investors enabling the advancement of its proprietary drug delivery platform – polyNaut®.
Company Info
Location
cambridge, massachusetts, united states
Additional Info
ViaNautis, formerly known as SomaServe, was founded in 2018 as a spin-off from UCL under the leadership of CEO and serial entrepreneur, Dr Francesca Crawford. The company’s core mission is to exploit the unique capabilities of the revolutionary polyNaut® technology.